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Mast cell activation syndrome
Mast cell activation disease
Medical hypothesis
A B S T R A C T
Objectives: One-fifth of Covid-19 patients suffer a severe course of Covid-19 infection; however, the
specific causes remain unclear. Mast cells (MCs) are activated by SARS-CoV-2. Although only recently
recognized, MC activation syndrome (MCAS), usually due to acquired MC clonality, is a chronic
multisystem disorder with inflammatory and allergic themes, and an estimated prevalence of 17%. This
paper describes a novel conjecture explaining how MCAS might cause a propensity for severe acute
Covid-19 infection and chronic post-Covid-19 illnesses.
Methods: Observations of Covid-19 illness in patients with/without MCAS were compared with extensive
clinical experience with MCAS.
Results: The prevalence of MCAS is similar to that of severe cases within the Covid-19-infected
population. Much of Covid-19’s hyperinflammation is concordant with manners of inflammation which
MC activation can drive. Drugs with activity against MCs or their mediators have preliminarily been
observed to be helpful in Covid-19 patients. None of the authors’ treated MCAS patients with Covid-19
suffered severe infection, let alone mortality.
Conclusions: Hyperinflammatory cytokine storms in many severely symptomatic Covid-19 patients may
be rooted in an atypical response to SARS-CoV-2 by the dysfunctional MCs of MCAS rather than a normal
response by normal MCs. If proven, this theory has significant therapeutic and prognostic implications.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
Since December 2019, the Covid-19 pandemic, due to the SARS-
CoV-2 coronavirus, has been rapidly spreading throughout many
parts of the world. It has been calamitous to the personal health
and finances of millions and also–largely due to the infection’s high
mortality rate–to global healthcare systems and societal economic
welfare. Approximately 15–20% of Covid-19-infected patients
suffer a severe form of the acute infection (Bulut and Kato,
2020; Rabec et al., 2020; Grasselli et al., 2020) hallmarked by
hyperinflammatory cytokine storms causing far more morbidity
and mortality than from any direct viral cytotoxicity. This has a
high mortality risk (Zhou et al., 2020a)– 50% in some
subpopulations (e.g. patients with cardiac injury or requiring
continuous renal replacement therapy)–(Fominskiy et al., 2020;
Shi et al., 2020; Bhatraju et al., 2020; Chen et al., 2020) and requires
hospitalisation and, often, mechanical ventilation. The Covid-19
cytokine storm is characterised by rapid proliferation and hyper-
activation of T cells, macrophages, and natural killer cells, and the
overproduction of >150 inflammatory cytokines and chemical
mediators released by immune or nonimmune cells (Sun et al.,
2020; Mangalmurti and Hunter, 2020). Among these inflammatory
cells, mast cells (MCs) may play an important role because when
they recognise viral products, they are activated and synthesise
many chemokines and cytokines. In addition, some cytokines
secreted by other cells such as T cells, damaged epithelial and
endothelial cells (Mukai et al., 2018), or even by themselves
(Hermans et al., 2019), stimulate MC activation. MCs regulate the
functions of immune cells such as dendritic cells, monocytes/
macrophages, granulocytes, T cells, B cells and NK cells. They also
recruit immune cells to inflamed tissue by secreting chemokines
and other mediators which locally increase vascular permeability
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(Abraham and St John, 2010; Krystel-Whittemore et al., 2016; St
John et al., 2011).
The roles of MCs in coronavirus-induced inflammation (Kritas
et al., 2020; Kılınc and Kılınc, 2020; Theoharides, 2020; Zhou et al.,
2020b) and cytokine storms (Theoharides, 2020) have been
recently discussed. Although MCs can recognise viruses by diverse
mechanisms (e.g. Toll-like receptor 3 detection of viral double-
stranded ribonucleic acid (RNA), viral sphingosine-1-phosphate
(S1P) binding to S1P receptors, and retinoic acid-induced gene I
(RIG-I) recognition of uncapped viral RNA) (Criado et al., 2020),
they also express angiotensin converting enzyme 2 (ACE2), now
known as the principal receptor for SARS-CoV-2, thus defining a
route by which MCs could also become hosts for this virus
(Theoharides, 2020). MCs also express many serine proteases
(including tryptase), which are necessary for SARS-CoV-2 infection
(Theoharides, 2020). Some risk factors for a severe form of Covid-
19 infection have been identified (e.g. older age, obesity and/or
other chronic pre-existing illness); however, specific mechanisms
by which such factors would permit more severe infection remain
unclear. After an acute infection with Covid-19, many people soon
manifest a variety of chronic and often inflammatory multisystem
illnesses (Wang et al., 2020; Bulut and Kato, 2020; Scala and Pacelli,
2020; Troyer et al., 2020; Hays, 2020).
Another mystery about the Covid-19 pandemic is why the
infection is mildly symptomatic or even asymptomatic in the
majority of those who are infected but is severely symptomatic,
often life-threatening, in a sizeable minority. In other words, what
causes the immune system to so catastrophically suddenly
overreact in certain Covid-19 patients while remaining properly
regulated in the majority? Another important question regards the
aetiology of chronic post-Covid-19 illnesses. Although solid data
on which these questions can be answered are not yet available,
this paper summarises the evidence suggesting that mast cell
activation disease–the majority of which comprises the prevalent,
but only recently recognised, mast cell activation syndrome
(MCAS)–fits very well with these puzzling observations.
This study offers a potentially important conjecture spurred by
(1) familiarity (across several thousand cases over the last dozen
years) with MCAS (mainly presenting as a chronic multisystem
polymorbidity of general MC-mediator-driven themes of inflamma-
tion  allergic-type issues) (Afrin et al., 2016a; Afrin et al., 2020) and
(2) the theory that Covid-19 inflammatory illnesses may be due to
abnormal hyperactivationby SARS-CoV-2 of the dysfunctional, likely
mutated portion of the MC population underlying primary MCAS, as
opposed to normal activation of normal MCs by the virus.
Primary MCAS has been thought by some to underlie, to at least
some extent, many of the risk factors identified thus far for severe
Covid-19 infection (Afrin, 2016b). MCAS is known to permanently
escalate its baseline level of dysfunction of the affected MCs shortly
after a major stressor (likely due to acquisition–due to complex
interactions between epigenetic abnormalities and the stressor’s
induced cytokine storm–of additional mutations by the mutated
stem cells from which the mutated/dysfunctional MCs are derived)
(Molderings, 2015; Haenisch et al., 2014; Molderings, 2016;
Altmüller et al., 2017; Haenisch et al., 2012; Molderings et al.,
2010; Molderings et al., 2007). As such, the assortment of
(generally inflammatory) post-Covid-19 illnesses seen in many
Covid-19 patients would be a natural course for MCAS. In fact,
Covid-19 would be far from the first infection for which post-
infectious chronic multisystem inflammatory illness is increasing-
ly being suspected to be rooted in (initiation of, or more likely
escalation of pre-existing) MCAS (e.g. Epstein-Barr virus infection,
tick-borne infections) rather than chronic active infection (Afrin,
2016b, Kempuraj et al., 2020). Again, since MCAS is a chronic
multisystem inflammatory disease (with intermittent acute flares)
if it is nothing else, it is possible that at least some of the patients
previously thought to have suffered repeat bouts of Covid-19
infection might have only suffered an initial bout of infection
followed some time later by symptomatic flaring of escalated
MCAS (e.g. fatigue, myalgias).
Of further interest, estimates of MCAS prevalence (17%, at least
in the developed world) (Molderings et al., 2013) closely
correspond with estimates of prevalence of severe Covid-19
infection. MCs–present in all vascularised tissues but dominant
at the environmental interfaces and in vessel walls (Akin and
Metcalfe, 2004)–are activated by the SARS-Cov-2 coronavirus
which causes Covid-19 infection (Kritas et al., 2020; Theoharides,
2020; Zhou et al., 2020b), leading to MC activation and resulting
release of various subsets of the MC’s >1000 potent multi-action
mediators (Ibelgaufts, 2020), including: biogenic amines (e.g.
histamine), proteases (e.g. tryptase and chymase), cytokines (e.g.
interleukins and TNF-α), eicosanoids (e.g. prostaglandins and
leukotrienes), heparin, and growth factors, at least some of which
are increasingly thought to play key roles in driving the hyper-
inflammation of severe Covid-19 illness (Kempuraj et al., 2020;
Valent et al., 2020).
A significant number of fatal cases of Covid-19 infection are
due to cardiovascular complications such as pulmonary embo-
lism, thromboembolism, sepsis and multiorgan failure. It has
been shown that MCs play a significant role in promoting
thrombotic diseases and complications; it has also been shown
that stabilising MCs helps to prevent fatal sepsis (Ramos et al.,
2010). As another example, neuropsychiatric disease appears
common in both MCAS (Afrin et al., 2015) and Covid-19 illness
(Romero-Sánchez et al., 2020), and although the acute and
subacute neurological disease in Covid-19 illness is thought to be
principally due to inflammation-induced coagulation, the authors
conjecture that chronic neuropsychiatric symptoms may be due
more to escalated (and likely pre-existing) MCAS. Additionally,
some of the drugs or drug classes at least preliminarily shown to
be helpful in modulating the severity of Covid-19 infection (e.g.
famotidine (Freedberg et al., 2020) and aspirin) (Viecca et al.,
2020), and for which anti-viral actions seem extremely unlikely,
have actions which include inhibiting MC activation or antago-
nising released MC mediators. Other drugs or drug classes with
activity against MCs or their released mediators have been
proposed for, or are actively involved in, trials against Covid-19
infection, including: cromolyn (Sestili and Stocchi, 2020; Sepay
et al., 2020; Gigante et al., 2020), flavonoids (Theoharides, 2020),
leukotriene inhibitors (Almerie and Kerrigan, 2020), Janus kinase
(JAK) inhibitors (Goker Bagca and Biray Avci, 2020; Seif et al.,
2020; Luo et al., 2020; Spinelli et al., 2020; Meyer et al., 2020),
dexamethasone (Meyer et al., 2020; RECOVERY Collaborative
Group et al., 2020), low-dose naltrexone (Sims, 2020), quercetin
(Onal, 2020; Colunga Biancatelli et al., 2020), and ascorbic acid
(Colunga Biancatelli et al., 2020).
MCAS remains a relatively unrecognised entity, despite its great
prevalence, which has likely been ‘camouflaged’ by its extreme
heterogeneity of clinical presentation (Afrin et al., 2016a; Afrin
et al., 2017), as driven by its underlying extreme mutational
heterogeneity. Although MCAS in some patients may be purely
secondary to another process (e.g. autoimmunity or cancer), it
clearly is a primary disease for those in whom it is currently
possible to demonstrate MC-relevant clonality in the clinical
laboratory. This is performed either by KIT mutation analysis
(currently largely limited to probing by polymerase chain reaction
for codon 816 mutations, almost always present in mastocytosis
but rarely found in MCAS) or by flow cytometry for cell surface co-
expression of CD117 together with either CD25 and/or CD2. In the
majority of MCAS cases, the disease is currently ‘idiopathic’, solely
because clonality cannot be demonstrated through the available
clinical testing. Studies to date have consistently shown, via
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sequencing of MC isolates obtained from MCAS patients, that the
MCs in almost all MCAS patients bear a wide variety of mutations
across KIT (just not in codon 816) and also dozens of other MC
regulatory genes (Molderings et al., 2007; Molderings et al., 2010;
Afrin et al., 2016c; Altmüller et al., 2017).
Therefore, mainly due to this extreme clinical heterogeneity
and recent recognition of the existence of the disease (implying
that most physicians remain unaware of it), most MCAS patients
remain undiagnosed and untreated, and therefore their dysfunc-
tional MCs, whether causing mild or severe illness, are uncon-
trolled and may react inappropriately to SARS-CoV-2 (Table 1).
Another confounding issue is that many MCAS patients who have
been undiagnosed for decades tend to minimise their problems,
sometimes deceivingly declaring themselves as ‘healthy’. This
perhaps accounts for some of the many severe Covid-19 patients
described as ‘healthy’ prior to infection. In the authors' own MCAS
patients (i.e., patients already diagnosed and treated, and thus
already with at least partial control over their MCAS; note many of
these patients had long suffered severe courses of MCAS prior to
diagnosis and having it brought under at least partial control with
treatment) who have come to suffer Covid-19 infection, none of
them have suffered a severe course of the infection (i.e., none have
required mechanical ventilation, let alone died), and we conjecture
it is precisely because their dysfunctional MCs were already under
at least partial control throughout the acute infection that they
have not suffered severe courses, though their MCAS still places
them at increased risk for developing post-infectious illness
(Figure 1).
Based on current knowledge, Covid-19 infection causes mild to
moderate symptoms in the majority of patients. However, these
early data also suggest that even if symptoms are just ‘mild to
moderate’ during the acute infection, fibrotic lung damage
develops in some, potentially leading to long-term complications
for a subset of patients (Spagnolo et al., 2020; Leask, 2020;
Lechowicz et al., 2020; George et al., 2020). It is well known that
over-activated MCs play a crucial role in the development of
fibrotic conditions. Given that up to 17% of the population is
generally pre-disposed to developing syndromes and diseases
related to MC activation (Molderings et al., 2013), it is conceivable
that people with this predisposition might have increased risk of
developing the chronic respiratory, neurologic or other illnesses
increasingly being seen following acute Covid-19 illness. Further-
more, the MC activation induced by Covid-19 infection could
increase the risk of poor outcomes in undiagnosed or uncontrolled
MCAS patients. Lung biopsies from Covid-19 patients clearly show
a significantly increased number of activated MCs compared to
healthy controls, demonstrating an important role of MCs during
Covid-19 infections (Zhou et al., 2020b).
MCAS-targeted therapy (e.g. inexpensive, safe histamine H1 and
H2 receptor antagonists) immediately upon recognition or suspi-
cion of onset of Covid-19 illness might mitigate the severity of the
illness. The impact on reducing hospitalisations, morbidity and
mortality warrants further investigation. Evaluation of MCAS in
patients who develop chronic post-Covid-19 illnesses is also
recommended.
The fact that MCs normally activate in response to infection
precludes diagnostic testing for MCAS (i.e. testing for elevated
levels in blood and urine of mediators relatively specific to MCs
such as tryptase, heparin, histamine and derivatives, prostaglandin
D2 and derivatives) (Afrin et al., 2020; Afrin and Molderings, 2014)
during acute Covid-19 infection. However, the potential personal
and societal implications of the conjecture described here are huge
and rapid formal investigation is recommended. Such investiga-
tion should include, at a bare minimum, a pilot clinical trial
empirically initiating MCAS-targeted therapy in patients newly
presenting with suspected Covid-19 illness and in whom careful
history-taking (regardless of the initially asserted state of prior
health) reveals chronic inflammatory and/or allergic issues
suspicious for MCAS. Initial empiric MCAS-targeted therapy could
include at least histamine H1 and H2 receptor antagonists. Note
that most MCAS-targeted therapies are sufficiently safe to make
their empiric initiation reasonable.
The signalling networks in all inflammatory diseases are
extremely complex, and other inflammatory cells besides MCs
are inescapably involved in generating the hyperinflammation of
Covid-19 infection (e.g. the extreme hyperferritinaemia seen in
some cases might easily be a macrophage activation syndrome or
secondary haemophagocytic lymphohistiocytosis sparked by a
Covid-19-driven escalation of MCAS more so than direct virus-
driven macrophage activation, given that hyperferritinaemia is
certainly not seen in all patients with severe Covid-19 infection)
(Gómez-Pastora et al., 2020; Ruscitti et al., 2020; Ruan et al., 2020;
Mehta et al., 2020). However, it is felt that the clinical patterns seen
thus far in the Covid-19 population suggest that MCAS (likely pre-
existing) is the root issue in many, perhaps even most, of those
suffering ‘severe’ infection.
The role that cytokine storms play in severe cases of Covid-19 is
what would be expected if the conjecture described here is correct.
Hyperactive MCs can get into a continuous activation loop, leading
to cytokine storms which can result in the fluid build-up and
pulmonary and other damage often seen in severe Covid-19
patients. In sum, although most MCAS patients do not present with
Covid-19-like hyperinflammation, MCAS is an extraordinarily
heterogeneous disease and it is felt that MCAS (likely pre-existing)
‘fits’ well with most of the behaviours of severe Covid-19 infection
observed thus far. Blocking MC mediators in Covid-19 patients may
Table 1
Organ and system involvement in mast cell activation syndrome. Conditions highlighted in bold are also seen in Covid-19 acute infection and/or post-infectious syndrome.
Organ/system Symptom/finding
Constitutional Fatigue, fevers, chills, weight loss, weight gain
Ears, nose and throat Conjunctivitis, rhinitis, sinusitis, dysosmia/anosmia, tinnitus, hearing loss, dysgeusia/ageusia, sore throat
Neurologic Headaches, migraines, brain fog, anxiety, depression, insomnia, seizures
Cardiovascular Chest pain, palpitations, hypotension
Pulmonary Cough, dyspnoea, wheezing
Urogenital Frequency, urgency, dysuria, pelvic pain
Oesophageal Heartburn, dysphagia, globus, chest pain
Stomach Dyspepsia, nausea, vomiting
Small intestine/colon Bloating, food intolerance, abdominal pain, diarrhoea, constipation
Hepatic Elevated transaminases, hepatomegaly
Salivary Glands Swelling
Lymphatics Lymphadenopathy
Dermatologic Flushing, pruritis, urticaria, haemangiomas, nodules, rashes, alopecia
Musculoskeletal Myalgias, arthralgias, oedema
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help calm MCs and cytokine storms, which may result in better
outcomes, including lower mortality rates. Furthermore, using MC
stabilisers such as antihistamines and cromolyn may help to
prevent a significant increase in post-Covid-19 chronic illnesses,
which in a significant proportion of such patients may be driven by
chronic persistent MC activation. These MC-targeted treatment
suggestions may be relevant for all Covid-19 patients, not just
those with pre-existing MC diseases.
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